ClinicalTrials.gg
CompletedNCT04564066Updated Apr 5, 2021

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

A Phase 1 interventional study of efgartigimod IV and efgartigimod PH20 SC in Healthy Volunteers, sponsored by argenx. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-05.

Sponsored by argenx · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study will compare the pharmacodynamics, pharmacokinetics and safety of efgartigimod as an intravenous infusion with efgartigimod as a subcutaneous injection in healthy adults.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject is between 18 and 65 years of age, inclusive, on the day when the ICF is signed.
  2. The subject is either male or female of non- ( [defined by continuous amenorrhea for at least 1 year without an alternative medical cause with a follicle-stimulating hormone (FSH) of >33.4 IU/L; in subjects on hormonal replacement therapy, a historical value pretreatment of >33.4 IU/L will be accepted as proof of menopausal status]) OR have a documented permanent sterilization procedure (ie, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
  3. The female subject has a negative pregnancy test at day -1
  4. The subject has a (BMI) between 18 and 30 kg/m2, inclusively, with a weight of ≥50 kg and ≤100 kg at screening.
  5. The subject is able to understand the requirements of the study, provide written (including consent for the use and disclosure of research-related health information), willing and able to comply with the protocol procedures (including required study visits).
  6. The subject is in good physical and mental health, per the opinion of the investigator, based on medical history, physical examination, , and vital sign findings; and biochemistry, hematology, virology, and urinalysis test results prior to the first IMP administration.
  7. The non-sterilized male subject who is sexually active with a female partner of childbearing potential must use effective (failure rate of \<1% per year). Male subject practicing true sexual abstinence (when consistent with the preferred and usual life style of the participant) can be included. The sterilized male subject who has had a vasectomy with documented aspermia postprocedure can be included. In addition, no male subject will be allowed to donate sperm during the period from signing the ICF, throughout the duration of the trial, and 90 days after the last administration of the IMP.
  8. The condition of the skin tissue on the subject's abdomen must allow for absorption and assessment of local safety of the planned SC injection, as determined by the investigator.
  9. The subject agrees to discontinue and refrain from all medications (including over-the-counter and/or prescription medications), except for occasional paracetamol use (maximum dose of 2 g/day and maximum of 10 g/2 weeks), antacid use, and ibuprofen use (maximum dose of 400 mg/day and not to be coadministered with antacid), at least 2 weeks before the first IMP administration through the final follow-up visit on day 78.
  10. The subject agrees to withhold from strenuous activities from at least 2 weeks before the first IMP administration through the final follow-up visit on day 78.
  11. The subject is a non-smoker and does not use any nicotine-containing products. A non-smoker is defined as an individual who has abstained from smoking for at least 1 year prior to screening.
  12. The subject has a negative nicotine analyte test at screening and on day -1.
  13. The subject has a negative urine drug screen (amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, and tricyclic antidepressants) at screening and on day -1.
  14. The subject has a negative alcohol urine test at screening and on day -1.
  15. The subject has a body temperature of 35.2°C to 37.6 °C at screening and on day -1.

Exclusion criteria

Exclusion Criteria:

  1. The subject has previously participated in clinical studies with efgartigimod (ARGX-113) and was administered an IMP.
  2. The subject has a known to 1 of the components in the IMP, or a history of severe allergic or anaphylactic reactions, in the opinion of the investigator.
  3. The subject tests positively at screening for any of the following conditions: a. The subject has an active infection (acute or chronic) at screening as determined by hepatitis B serology.

    b. The subject has serology positive for virus antibody (HCV Ab). c. The subject has (HIV) positive serology.

  4. Subjects with active or chronic uncontrolled bacterial, viral, or fungal infection at screening.
  5. Subjects with clinical evidence of other significant serious diseases, subjects who underwent a recent major surgery, or any other reason which could confound the results of the trial or put the subject at undue risk.
  6. The subject has total IgG \<6 g/L at screening.
  7. The subject has presence or sequelae of gastrointestinal, liver, kidney, or any other condition known to potentially interfere with the absorption, distribution, metabolism, or excretion of IMP.
  8. The subject has a history of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before first IMP administration. Subjects with the following cancer can be included anytime:

    1. Adequately treated basal cell or squamous cell skin cancer
    2. Carcinoma in situ of the cervix
    3. Carcinoma in situ of the breast or
    4. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)
  9. The subject has a clinically relevant abnormality detected on recording regarding either rhythm or conduction (eg, >450 ms for male and QTcF >470 ms for female subjects, or a known long QT syndrome). A first-degree heart block or sinus arrhythmia will not be considered a significant abnormality.
  10. The subject has clinically relevant abnormalities detected in vital sign measurements prior to dosing.
  11. The subject has significant blood loss (including blood donation >500 mL) or has had a transfusion of any blood product within 12 weeks prior to the (first) IMP administration or a scheduled transfusion within 4 weeks after the end of the study.
  12. The subject has been treated with any drug known to have a well-defined potential for toxicity to a major organ in the last 3 months preceding the initial IMP administration.
  13. The subject has a history of consuming more than 21 units of alcoholic beverages per week or a history of alcoholism or drug/chemical/substance abuse within 2 years prior to screening (Note: 1 unit = 330 mL of beer, 110 mL of wine or 28 mL of spirits). Regular consumption of a large quantity of coffee, tea ( >6 cups per day), or equivalent within 3 weeks prior to first dose is also exclusionary.
  14. The subject has received drug within 3 months or 5 half-lives of the drug (whichever is longer) prior to first IMP administration.
  15. The subject has received a vaccination (eg, influenza vaccine) within the last 4 weeks prior to screening.
  16. The subject has received any systemic agent within 6 months prior to the initial IMP administration.
  17. The subject has received any systemic within 3 months prior to the initial IMP administration.
  18. The subject has received any monoclonal antibody, within 6 months prior to first IMP administration.
  19. The subject is an employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as a family member of an employee or the investigator.
  20. The subject has any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.
  21. The subject has any condition impairing phlebotomy.
  22. The subject is a pregnant or lactating women or intending to become pregnant during the study or within 90 days after last dosing.
  23. The subject has a positive nasopharyngeal PCR test for SARS-CoV-2 on days -2 or -1. 24. The subject has had any contact with SARS-CoV-2 positive or COVID-19 patients within the last 2 weeks prior to admission to the clinical research center.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    efgartigimod IV

    intravenous infusions of efgartigimod

    Biological: efgartigimod IV

  • Experimental
    efgartigimod PH20 SC

    subcutaneous injections of efgartigimod PH20 SC

    Biological: efgartigimod PH20 SC

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage reduction in total IgG levels, compared to baseline, at day 29 (week 4), 7 days after the fourth IV or SC administration of efgartigimod

    Time frame: After four weeks (day 29)

Secondary outcomes

  1. Percentage reduction in total IgG levels at all other assessment timepoints as of week 4

    Time frame: Up to 15 weeks

  2. Percentage reduction in levels of IgG subtypes (IgG1, IgG2, IgG3, and IgG4) at all assessment timepoints

    Time frame: Up to 15 weeks

  3. Absolute values and changes from baseline in total IgG levels at all assessment timepoints

    Time frame: Up to 15 weeks

  4. Absolute values and changes from baseline in levels of IgG subtypes (IgG1, IgG2, IgG3, and IgG4) at all assessment timepoints

    Time frame: Up to 15 weeks

  5. AUEC for percentage reduction in total IgG levels per weekly interval after each dose (week 1, week 2, week 3, and week 4), over the interval week 1 to week 4, and over the entire study period (week 1 to week 11)

    Time frame: Up to 11 weeks

  6. AUEC for percentage reduction in IgG levels for each subtype per weekly interval after each dose (week 1, week 2, week 3, and week 4), over the interval week 1 to week 4, and over the entire study period (week 1 to week 11)

    Time frame: Up to 11 weeks

  7. Serum levels of efgartigimod and derived PK parameters

    Time frame: Up to 15 weeks

  8. Cmax of efgartigimod

    Time frame: Up to 15 weeks

  9. Ctrough of efgartigimod

    Time frame: Up to 15 weeks

  10. Lymphocyte count

    Time frame: Up to 15 weeks

  11. Neutrophil count

    Time frame: Up to 15 weeks

  12. Monocyte count

    Time frame: Up to 15 weeks

  13. Vital sign measurement: blood pressure

    Time frame: Up to 15 weeks

  14. Vital sign measurement: heart rate

    Time frame: Up to 15 weeks

  15. ECG recording of QTcF

    Time frame: Up to 15 weeks

  16. Incidence and characterization of TEAEs

    Time frame: Up to 15 weeks

07

Study locations

1 site
  • Study Site 1
    Groningen, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Dec 2020, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2020
First posted
Sep 25, 2020
StartActual
Aug 18, 2020
Primary completionActual
Dec 24, 2020
CompletionActual
Feb 11, 2021
Last update
Apr 5, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04564066
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Aug 18, 2020
Primary completion
Dec 24, 2020
Completion
Feb 11, 2021
Last update
Apr 5, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion